



- (51) **International Patent Classification:**
A61K 31/7028 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2014/034654
- (22) **International Filing Date:**
18 April 2014 (18.04.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 61/813,499 | 18 April 2013 (18.04.2013) | US |
| 61/826,311 | 22 May 2013 (22.05.2013) | US |
| 61/834,415 | 12 June 2013 (12.06.2013) | US |
| 61/891,609 | 16 October 2013 (16.10.2013) | US |
| 61/946,317 | 28 February 2014 (28.02.2014) | US |
- (71) **Applicant:** IMMUNE DESIGN CORP. [US/US]; 1616 Eastlake Ave E., Suite 310, Seattle, WA 98102 (US).
- (72) **Inventors:** PAYA CUENCA, Carlos, V.; 165 Collingwood Street, San Francisco, CA 94114 (US). TER MEULEN, Jan, Henrik; c/o Immune Design Corp., 1616 Eastlake Ave E., Suite 310, Seattle, WA 98102 (US).
- (74) **Agents:** DOLA, Kristen, A. et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** GLA MONOTHERAPY FOR USE IN CANCER TREATMENT

(57) **Abstract:** The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.

